New guidelines provide direction on molecular testing for patients who could benefit from targeted lung cancer treatment.
Even when accounting for competing risks, data shows that patients with lung cancer who are HIV-infected have a worse prognosis than those who are noninfected.
For the subset of patients with non-small cell lung cancer who are ALK-positive, targeted therapy offers the potential for improved long-term outcome.
This fact sheets answers common questions patients may have about the link between cigar smoking and cancer.
This patient fact sheet contains information on the different types of tumors as well as an overview of available biomarker tests and personalized medicine.
While the incidence of lung cancer in males has decreased over the last few decades, the rates of the disease have doubled in women.
In addition to crizotinib, other targeted therapies for NSCLC are currently in development.
Editorial Advisory Board member Dr. Socinski discusses the key clinical insights brought to light by the POINTBREAK trial, presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.
Results of the National Lung Screening Trial have led to new recommendations for individuals at high risk for lung cancer.
Cancer patients who smoke are notoriously reluctant to give up the habit, but a cancer diagnosis may present a unique educational moment.
This slideshow reviews Abraxane® Injectable Suspension (paclitaxel protein-bound particles (albumin-bound) for patients with non-small cell lung cancer.
Table of Contents
Slide 3: ...
By Sandra Cuellar, PharmD, BCOP
A 63-year-old male is referred by his primary care physician for work-up of possible lung cancer. ...
By Tara Morrison, MD; Yu-Ning Wong, MD, MSCE
A 66-year-old African American man presented with a several month history of weight ...
More people in the United States die from lung cancer than any other type of cancer. This is true for ...
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|